ATNX - ATNX STOCK NEWS

Athenex, Inc. (NASDAQ: ATNX) announces the appointment of Mr. Joe Annoni as the new Chief Financial Officer, effective immediately. With over 20 years of experience in finance, including roles in private equity and investment banking, Annoni aims to strengthen Athenex’s financial foundation and enhance shareholder value. CEO Johnson Lau emphasizes the importance of Annoni's leadership at this critical time for the company.

Athenex focuses on developing innovative cancer therapies and operates across several platforms, including oncology and global supply chain.

ImmunityBio, Inc. (NASDAQ: IBRX) has completed its acquisition of a leasehold interest in a pharmaceutical manufacturing facility from Athenex, Inc. (NASDAQ: ATNX) in Dunkirk, New York. This 409,000 square foot facility enhances ImmunityBio's capabilities for large-scale vaccine and immunotherapy production. The site includes clean rooms for manufacturing activities and is expected to significantly expand ImmunityBio's production capacity while reducing capital costs. This strategic move aligns with ImmunityBio's growth plans and aims to accelerate product development.

Athenex, Inc. (NASDAQ: ATNX) has finalized the sale of its leasehold interest in a manufacturing facility in Dunkirk, New York, to ImmunityBio, Inc. for approximately $40 million. This strategic move aims to strengthen Athenex's financial standing by using part of the proceeds to address its debt obligations and fund corporate purposes. Chief Operating Officer Jeffrey Yordon expressed optimism about partnering with ImmunityBio and highlighted the facility’s state-of-the-art capabilities. Further details can be found in a Form 8-K filed with the SEC.

Athenex, a biopharmaceutical company focused on cancer treatment, announced its participation in the 11th Annual SVB Leerink Global Healthcare Conference. The presentation will take place on February 17, 2022, at 3:00 P.M. ET, featuring CEO Johnson Lau and President Daniel Lang. A live audio webcast will be accessible on Athenex's website, with a replay available for 90 days. Athenex, founded in 2003, aims to innovate in cancer therapies through three platforms and various core technologies, including Orascovery and Cell therapy.

Athenex, Inc. (NASDAQ: ATNX) has announced a definitive agreement for ImmunityBio, Inc. (NASDAQ: IBRX) to acquire its Dunkirk, New York manufacturing facility and related assets for approximately $38 million. The transaction aims to improve Athenex's financial standing by servicing debt and funding corporate needs. Following the sale, Athenex will retain its headquarters and continue operations of its divisions. The deal is expected to close in Q1 2022 and includes provisions for Athenex to manufacture certain products at the Dunkirk facility.

ImmunityBio has entered into a definitive agreement to acquire a leasehold interest in a 409,000 square foot cGMP manufacturing facility in Dunkirk, New York, from Athenex (NASDAQ: ATNX). This facility will enable the production of one billion doses of RNA and adjuvant vaccines, significantly enhancing ImmunityBio's manufacturing capabilities. The investment aims to expedite the company's development and commercialization of immunotherapy and vaccine products, with production expected to commence in Q4 2022. The acquisition bolsters ImmunityBio's global manufacturing capacity.

Athenex announced a virtual Key Opinion Leader event to discuss its CAR-NKT cell therapy platform today at 9:00 a.m. ET. Interim results from the ANCHOR study on KUR-502 show an impressive 80% Overall Response Rate and 60% Complete Response at lower dose levels. In the study, five patients achieved significant responses, including a recent conversion of a partial response to complete response. The safety profile remains favorable, and enrollment continues. KOLs from Baylor and MD Anderson will present findings and insights during the webinar.

Athenex, Inc. (NASDAQ: ATNX) will host a virtual key opinion leader event on December 13, 2021, at 9 AM ET, focusing on CAR-NKT technology. The webinar will feature experts from Baylor College of Medicine and MD Anderson Cancer Center discussing interim data from the ANCHOR study evaluating KUR-502 in relapsed or refractory lymphomas and leukemias. The findings will also be presented at the ASH Annual Meeting, December 11-14. A Q&A session will follow the presentations, and registration details are available through the provided link.

Athenex, Inc. (NASDAQ: ATNX) announced that its Marketing Authorization Application (MAA) for oral paclitaxel and encequidar for the treatment of advanced breast cancer has been validated by the UK’s MHRA for review. The MAA is set for a 150-day assessment period which will determine the product's approvability. This milestone underscores Athenex's commitment to providing innovative treatment options for patients. The MAA is based on a pivotal Phase III study that demonstrated significant improvements in safety and efficacy, achieving its primary endpoint against IV paclitaxel.